. Author manuscript; available in PMC: 2011 Aug 1.

Published in final edited form as: Am J Obstet Gynecol. 2010 Apr 24;203(2):162.e1–162.e8. doi: 10.1016/j.ajog.2010.02.056

Table 5.

Log₁₀(IC₅₀) values for HER-2/neu overexpressors versus low expressors treated with single-agent chemotherapies.

Chemotherapy	mean±SD, log₁₀(IC₅₀) values		P^†	Fold decrease^‡ in IC₅₀
Chemotherapy	HER-2/neu negative	HER-2/neu positive	P^†	Fold decrease^‡ in IC₅₀
Carboplatin (µM)	1.456±0.120	0.738±0.173	0.0059	5.22
Cisplatin (µM)	0.385±0.068	−0.345±0.238	0.0262	5.37
Cyclophosphamide (µM)	0.852±0.417	0.257±0.041	0.2912	3.94
Docetaxel (nM)	0.631±0.384	0.460±0.093	0.5240	1.48
Doxorubicin (nM)	2.064±0.752	1.132±0.069	0.1639	8.55
Etoposide (µM)	0.025±0.478	−0.479±0.098	0.2053	3.19
Fluorouracil (µM)	1.428±0.384	0.853±0.412	0.2309	3.76
Gemcitabine (nM)	1.291±0.490	0.602±0.062	0.1330	4.89
Ifosfamide (µM)	1.229±0.395	0.962±0.210	0.5061	1.85
Paclitaxel (nM)	0.741±0.209	0.721±0.464	0.9506	1.05
Topotecan (nM)	1.917±0.547	1.025±0.017	0.1056	7.80
Vinblastine (nM)	0.353±0.481	0.224±0.064	0.7692	1.35
Vincristine (nM)	1.191±1.281	0.699±0.333	0.6826	3.10
Vinorelbine (nM)	0.816±0.367	0.810±0.236	0.9858	1.01

^†

P value, unequal-variance t-test.

^‡

Fold decrease (positive compared to negative) in IC₅₀ (original units as shown), calculated as 10 to the power (difference in mean log₁₀(IC₅₀)s between groups).